Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis

Apogee Therapeutics, Inc.

Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.
Interim safety and pharmacokinetic data from the Phase 1 trial expected in 2025.
Plans to start combination trial of APG777 (IL-13) and APG990 in 2025 for broader efficacy in atopic dermatitis.
CEO Michael Henderson: three programs advanced into clinical trials in 12 months since company's inception.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.